



Supplementary Fig. S7: Validation of *TBX2-AS1* expression in NBL cell lines and impact on NBL cell growth. (A) Expression of *TBX2-AS1* and *TBX2* across pediatric cancers. (B) Comparison of expression levels of *TBX2*, *TBX2-AS1*, *MYCN*, and *MYCNOS* in the NBL TARGET (un-stranded) and NBL GMKF (stranded) RNA-sequencing cohorts show high concordance. Pearson's correlation between the 14 common samples for these genes was $r=0.979$, 0.954 , 0.983 , and 0.877 , respectively. (C) Correlation between *TBX2-AS1* and other genes previously shown to be regulated by *TBX2*. (D) Expression of *TBX2-AS1* and *TBX2* in 38 NBL cell lines. (E) RT-qPCR validation of *TBX2-AS1* and *TBX2* expression in 8 NBL cell lines. (F) RT-qPCR expression of *TBX2-AS1* and *TBX2* for NLF cell line treated with non-targeting control (siNTC) and four different siRNAs targeting *TBX2-AS1*. si*TBX2-AS1-A* is referred to as si*TBX2-AS1* in the main figures. Three independent knockdown experiments are represented. (G) Western blot for *TBX2* expression after independent treatment of multiple siRNAs targeting *TBX2-AS1* in NLF. (H) Representative image of NLF cell growth as measured by RT-ces assay following siRNA treatments. siPLK1 is a positive control. Cell index is normalized to time point when siRNA reagent is added at 24 hours post cell plating. All si*TBX2-AS1* treatments resulted in significant growth inhibition. (I) RT-qPCR expression of *TBX2-AS1* and *TBX2* for SKNSH cell line treated with siNTC, si*TBX2-AS1*, and si*TBX2*. Three independent knockdown experiments are plotted, each plated in triplicate. (J) Representative Western blot for *TBX2* expression after si*TBX2* or si*TBX2-AS1* treatment compared to NTC in SKNSH. Right panel: Protein quantification derived from ImageJ analysis of Western blots for three independent knockdown experiments. (K) Representative image of SKNSH cell growth as measured by RT-ces assay following siRNA treatments. Cell index is normalized to time point when siRNA reagent is added at 24 hours post cell plating. Both si*TBX2-AS1* and si*TBX2* show significant growth inhibition, consistent with results observed for the NLF cell line. (L) RT-qPCR expression of *TBX2-AS1* and *TBX2* for SKNSH cell line treated with siNTC and four different siRNAs targeting *TBX2-AS1*. Two independent knockdown experiments are represented. (M) Western blot for *TBX2* expression after independent treatment of multiple siRNAs targeting *TBX2-AS1* in SKNSH. (N) Image of SKNSH cell growth as measured by RT-ces assay following independent treatments of four siRNAs targeting si*TBX2-AS1*. Cell index is normalized to time point when siRNA reagent is added at 24 hours post cell plating with index set to start at one.